Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials

Connect Biopharma Holdings Ltd

Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).
Cash, equivalents, short-term investments $31.5M at June 30, 2026; runway at least one year.
Enrollment completed in Phase 2 Seabreeze STAT asthma (160 pts) and COPD (159 pts) studies; topline results expected September 2026.
Initiated open-label Phase 2 Seabreeze STAT IV trial (40 participants) evaluating IV rademikibart for acute exacerbations.
Simcere license revenue $2.8M in Q2 (vs $48K prior year); eligible for up to ~$99M in remaining milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.